ZLDPF (Zealand Pharma AS) Institutional Ownership: 38.37% (As of Jul. 11, 2026)


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $44.86
GF Value $2,429.27
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Institutional Ownership?

Zealand Pharma AS ZLDPF 62 Institutional Ownership is 38.37% as of Jul. 11, 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $2,429.27 (Possible Value Trap). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zealand Pharma AS's institutional ownership is 38.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zealand Pharma AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zealand Pharma AS's Float Percentage Of Total Shares Outstanding is 0.00%.

Zealand Pharma AS Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Institutional Ownership Chart

Zealand Pharma AS Historical Data

The historical data trend for Zealand Pharma AS can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 45.78 45.64 45.49 46.21 46.80 46.94 43.42 43.76 41.97 41.95
ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 38.37% mean?
Zealand Pharma AS (ZLDPF) has a Institutional Ownership of 38.37% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Institutional Ownership too high?
Zealand Pharma AS's current Institutional Ownership is 38.37%. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Institutional Ownership compare to VRTX and REGN?
Zealand Pharma AS's Institutional Ownership of 38.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Institutional Ownership is 38.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,429.27, compared to a current price of $44.86 — trading 98.2% below its estimated fair value. The current Institutional Ownership is 38.37%. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current Institutional Ownership is 38.37% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $44.86 is trading 98.2% below its estimated GF Value™ of $2,429.27. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Institutional Ownership: 38.37%
  • GF Value™: $2,429.27 vs. price of $44.86 (98.2% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.86
Price
$2,429.27
GF Value